The move grants a new method of use patent to inhibit COVID-19 in patients with pneumonia and receiving supplemental oxygen at a fraction of inspired oxygen (FiO2) up to and including 60%.
The new patent, expiring in 2041, protects the results from a post-hoc analysis from the global Phase 2/3 study in hospitalized patients with COVID-19 pneumonia.
In the analysis of 251 participants requiring a FiO2 up to and including 60% at baseline (54% of study participants), oral opaganib resulted in a 62% reduction in mortality, improved outcomes in time to room air and median time to hospital discharge, and a reduced likelihood of intubation and mechanical ventilation.
Late-stage development of opaganib is ongoing pending Phase 3 trial design regulatory approvals and securing of external funding.
Price Action: RDHL shares are up 50.90% at $0.70 on the last check Wednesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.